Britain’s biggest drugmaker GlaxoSmithKline is moving ahead with Brexit contingency planning “right now,” including preparing a system to test drugs in the European Union if Britain crashes out of the bloc without a trade deal.

Britain’s pharmaceuticals industry failed to secure a judicial review of new cost curbs, which mean drugs costing NHS England more than 20 million pounds ($26 million) annually no longer get automatic funding.

AbbVie announced today a global resolution of all intellectual property-related litigation with Amgen over Amgen’s proposed biosimilar adalimumab product.

Europe’s drugs regulator could lose more than 70 percent of staff, making it unable to function, if politicians pick the wrong new home for the London-based agency, it warned on Tuesday.

The U.S. Food and Drug Administration approved Pfizer Inc.’s rare blood cancer drug Besponsa with a boxed warning.

A rare fungus that can cause drug-resistant infections has been found in around 200 patients in more than 55 hospitals across Britain, health officials said.

The supply of life-saving medicines in Europe could be severely disrupted unless Britain successfully negotiates a smooth and orderly exit from the EU, pharmaceutical industry leaders warned.

The UK Supreme Court ruled that generic drugmaker Actavis’ versions of the cancer drug Alimta directly infringe on certain Eli Lilly patents in Europe.

GlaxoSmithKline filed its new three-in-one inhaled lung drug for U.S. approval, potentially putting it on track to reach the market ahead of rivals in 2017.

The number of people with high blood pressure has almost doubled in 40 years to over 1.1 billion worldwide, scientists said, with the burden of the condition shifting from the rich to the poor.